Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1797616 | 0.82 | RAB9A (0.41) | GAADDAH1POLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2965203 | 0.80 | ALDH1A1 (0.35) | GAANPC1RAB9ASMN1; SMN2CYP3A4 | |
| Hydrochloric Acid SCHEMBL7451220 | 0.80 | TNKS2 (0.60) | POLBNPC1RAB9ASMN1; SMN2PDE10A | |
| SCHEMBL20677814 | 0.77 | DDAH1 (0.63) | GAADDAH1POLBNPC1RAB9A | |
| SCHEMBL6757274 | 0.76 | ALPL (0.62) | GAADDAH1POLBNPC1RAB9A | |
| SCHEMBL230157 | 0.74 | POLB (0.84) | GAADDAH1POLBNPC1RAB9A | |
| SCHEMBL230024 | 0.74 | GAA (0.78) | GAADDAH1POLBNPC1RAB9A | |
| SCHEMBL4113303 | 0.74 | DDAH1 (0.65) | GAADDAH1POLBNPC1RAB9A | |
| SCHEMBL6757226 | 0.72 | MAPK1 (0.66) | GAADDAH1POLBNPC1RAB9A | |
| Bendazol SCHEMBL29539948 | 0.72 | GAA (1.00) | GAADDAH1POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | claimed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | claimed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | claimed |
| US-20150201622-A1 | NEW ANTIMICROBIAL COMPOSITIONS AND USES THEREOF | CTT GROUP INC (CA) | 2015-07-23 | — | — | US | disclosed |
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | disclosed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | disclosed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | disclosed |
| EP-1244639-A4 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-02-05 | — | — | EP | disclosed |
| US-6495561-B2 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1244639-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | MERCK SHARP & DOHME CORP. | 2002-05-09 | — | — | US | disclosed |
| US-6380205-B1 | QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-03-14 | — | — | US | disclosed |
| US-6291499-B1 | TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001032634-A1 | 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055519-A1 | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | CHRM1 301/4885GAA 4642/4885DDAH1 702/4885 |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | CHRM1 223/4885GAA 4529/4885DDAH1 691/4885 |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | CHRM1 22/4885GAA 2812/4885DDAH1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.